Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
September 30, 2026 49.33%
June 30, 2026
March 31, 2026 64.84%
December 31, 2025 76.00%
September 30, 2025 -52.62%
June 30, 2025
March 31, 2025 79.02%
December 31, 2024 66.72%
September 30, 2024 73.16%
June 30, 2024 71.06%
March 31, 2024 67.92%
December 31, 2023 70.46%
September 30, 2023 70.14%
June 30, 2023 75.00%
March 31, 2023 72.83%
December 31, 2022 65.35%
September 30, 2022 66.98%
June 30, 2022 64.56%
March 31, 2022 65.41%
December 31, 2021 47.09%
September 30, 2021 70.25%
June 30, 2021 67.22%
March 31, 2021 65.41%
December 31, 2020 65.99%
September 30, 2020 63.97%
Date Value
June 30, 2020 60.49%
March 31, 2020 66.56%
December 31, 2019 62.23%
September 30, 2019 61.28%
June 30, 2019 69.31%
March 31, 2019 68.67%
December 31, 2018 72.28%
September 30, 2018 74.40%
June 30, 2018 78.11%
March 31, 2018 74.14%
December 31, 2017 75.73%
September 30, 2017 74.76%
June 30, 2017 73.21%
March 31, 2017 78.80%
December 31, 2016 75.58%
September 30, 2016 70.57%
June 30, 2016 76.47%
March 31, 2016 76.66%
December 31, 2015 73.15%
September 30, 2015 80.79%
June 30, 2015 79.59%
March 31, 2015 80.16%
December 31, 2014 78.92%
September 30, 2014 80.23%
June 30, 2014 82.52%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 54.92%
Corcept Therapeutics, Inc. 98.65%
Veru, Inc. --
Johnson & Johnson 68.11%
Eli Lilly & Co. 83.88%

Gross Profit Margin (Quarterly) Related Metrics